Trial Outcomes & Findings for Red Cell Storage Duration Study (NCT NCT00991341)

NCT ID: NCT00991341

Last Updated: 2015-06-09

Results Overview

The follow-up MODS used to calculate 7-day ΔMODS from pre-op baseline was based on the worst value of each component of MODS observed through post-op day 7, hospital discharge, or death, whichever occurred first, even if a subject's worst values for different components occurred on different dates. Subjects who died during this time period were assigned the worst possible follow-up MODS score, 24 points, and each component of MODS was set at 4, which is the worst score. If a subject did not die during this time period but had at least one day where the Glasgow Coma Score couldn't be scored \[subject sedated; neurologic function not normal by pre-op history (prior stroke, tumor or trauma sequelae, cognitively challenged, behavioral disorder, etc.) or intra-op history, but currently unable to assess because of sedation\], then a post-op MODS score was set to missing and a 7-day ΔMODS was not computed. The total MODS score ranges from 0 (best possible) to 24 points (worst possible).

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

1481 participants

Primary outcome timeframe

Through post-operative day 7, hospital discharge, or death, whichever occurs first

Results posted on

2015-06-09

Participant Flow

RECESS recruitment took place at 33 US hospitals, beginning in January 2010 and ending in January 2014.

Randomization was stratified by age (≥18 yrs or \<18 yrs) and by whether or not the subject was in the ICU prior to surgery. A subject could not be randomized unless prior to surgery but no earlier than one calendar day prior to surgery, the transfusion service had enough suitable units of both storage durations to satisfy the cross-match request.

Participant milestones

Participant milestones
Measure
Shorter-storage Red Blood Cell Units
Red blood cell units stored \<= 10 days Red blood cell units stored \<= 10 days: Pre-storage leukoreduced red blood cell units stored \<=10 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
Longer-storage Red Blood Cell Units
Red blood cell units stored \>= 21 days Red blood cell units stored \>= 21 days: Pre-storage leukoreduced red blood cell units stored \>=21 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
Overall Study
STARTED
742
739
Overall Study
COMPLETED
538
560
Overall Study
NOT COMPLETED
204
179

Reasons for withdrawal

Reasons for withdrawal
Measure
Shorter-storage Red Blood Cell Units
Red blood cell units stored \<= 10 days Red blood cell units stored \<= 10 days: Pre-storage leukoreduced red blood cell units stored \<=10 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
Longer-storage Red Blood Cell Units
Red blood cell units stored \>= 21 days Red blood cell units stored \>= 21 days: Pre-storage leukoreduced red blood cell units stored \>=21 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
Overall Study
no surgery w/in 30 days of randomization
11
18
Overall Study
Death
3
0
Overall Study
no RBCs received 96hrs after randomized
186
155
Overall Study
Physician Decision
1
2
Overall Study
Withdrawal by Subject
3
4

Baseline Characteristics

Red Cell Storage Duration Study

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Shorter-storage Red Blood Cell Units
n=538 Participants
Red blood cell units stored \<= 10 days Red blood cell units stored \<= 10 days: Pre-storage leukoreduced red blood cell units stored \<=10 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
Longer-storage Red Blood Cell Units
n=560 Participants
Red blood cell units stored \>= 21 days Red blood cell units stored \>= 21 days: Pre-storage leukoreduced red blood cell units stored \>=21 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
Total
n=1098 Participants
Total of all reporting groups
Age, Continuous
73 years
n=99 Participants
72 years
n=107 Participants
72 years
n=206 Participants
Age, Customized
<18 years
2 participants
n=99 Participants
2 participants
n=107 Participants
4 participants
n=206 Participants
Age, Customized
>= 18 years
536 participants
n=99 Participants
558 participants
n=107 Participants
1094 participants
n=206 Participants
Sex: Female, Male
Female
310 Participants
n=99 Participants
313 Participants
n=107 Participants
623 Participants
n=206 Participants
Sex: Female, Male
Male
228 Participants
n=99 Participants
247 Participants
n=107 Participants
475 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
13 Participants
n=99 Participants
19 Participants
n=107 Participants
32 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
506 Participants
n=99 Participants
513 Participants
n=107 Participants
1019 Participants
n=206 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
19 Participants
n=99 Participants
28 Participants
n=107 Participants
47 Participants
n=206 Participants
Race (NIH/OMB)
American Indian or Alaska Native
1 Participants
n=99 Participants
1 Participants
n=107 Participants
2 Participants
n=206 Participants
Race (NIH/OMB)
Asian
11 Participants
n=99 Participants
8 Participants
n=107 Participants
19 Participants
n=206 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
3 Participants
n=99 Participants
1 Participants
n=107 Participants
4 Participants
n=206 Participants
Race (NIH/OMB)
Black or African American
32 Participants
n=99 Participants
39 Participants
n=107 Participants
71 Participants
n=206 Participants
Race (NIH/OMB)
White
485 Participants
n=99 Participants
493 Participants
n=107 Participants
978 Participants
n=206 Participants
Race (NIH/OMB)
More than one race
2 Participants
n=99 Participants
3 Participants
n=107 Participants
5 Participants
n=206 Participants
Race (NIH/OMB)
Unknown or Not Reported
4 Participants
n=99 Participants
15 Participants
n=107 Participants
19 Participants
n=206 Participants
Region of Enrollment
United States
538 participants
n=99 Participants
560 participants
n=107 Participants
1098 participants
n=206 Participants
Weight
75 kg
n=99 Participants
74 kg
n=107 Participants
75 kg
n=206 Participants
Height
165 cm
n=99 Participants
165 cm
n=107 Participants
165 cm
n=206 Participants
Minimum TRUST Score
0
1 participants
n=99 Participants
0 participants
n=107 Participants
1 participants
n=206 Participants
Minimum TRUST Score
3
166 participants
n=99 Participants
222 participants
n=107 Participants
388 participants
n=206 Participants
Minimum TRUST Score
4
210 participants
n=99 Participants
196 participants
n=107 Participants
406 participants
n=206 Participants
Minimum TRUST Score
5
132 participants
n=99 Participants
113 participants
n=107 Participants
245 participants
n=206 Participants
Minimum TRUST Score
6
26 participants
n=99 Participants
27 participants
n=107 Participants
53 participants
n=206 Participants
Minimum TRUST Score
7
3 participants
n=99 Participants
2 participants
n=107 Participants
5 participants
n=206 Participants
ICU Status at Randomization
In ICU Before Surgery
34 participants
n=99 Participants
33 participants
n=107 Participants
67 participants
n=206 Participants
ICU Status at Randomization
Not in ICU Before Surgery
504 participants
n=99 Participants
527 participants
n=107 Participants
1031 participants
n=206 Participants
Baseline Multiple Organ Dysfunction Score
0
252 participants
n=99 Participants
293 participants
n=107 Participants
545 participants
n=206 Participants
Baseline Multiple Organ Dysfunction Score
1
223 participants
n=99 Participants
194 participants
n=107 Participants
417 participants
n=206 Participants
Baseline Multiple Organ Dysfunction Score
2
48 participants
n=99 Participants
57 participants
n=107 Participants
105 participants
n=206 Participants
Baseline Multiple Organ Dysfunction Score
3
10 participants
n=99 Participants
11 participants
n=107 Participants
21 participants
n=206 Participants
Baseline Multiple Organ Dysfunction Score
4
4 participants
n=99 Participants
4 participants
n=107 Participants
8 participants
n=206 Participants
Baseline Multiple Organ Dysfunction Score
5
1 participants
n=99 Participants
1 participants
n=107 Participants
2 participants
n=206 Participants
ABO Blood Group
O
209 participants
n=99 Participants
235 participants
n=107 Participants
444 participants
n=206 Participants
ABO Blood Group
A
240 participants
n=99 Participants
241 participants
n=107 Participants
481 participants
n=206 Participants
ABO Blood Group
B
64 participants
n=99 Participants
63 participants
n=107 Participants
127 participants
n=206 Participants
ABO Blood Group
AB
25 participants
n=99 Participants
21 participants
n=107 Participants
46 participants
n=206 Participants
Hemoglobin
11.7 g/L
n=99 Participants
12.0 g/L
n=107 Participants
11.9 g/L
n=206 Participants

PRIMARY outcome

Timeframe: Through post-operative day 7, hospital discharge, or death, whichever occurs first

Population: Analysis is restricted to evaluable subjects (defined as randomized subjects who underwent cardiac surgery within 30 days after randomization and received at least one RBC transfusion between randomization and post-operative hour 96).

The follow-up MODS used to calculate 7-day ΔMODS from pre-op baseline was based on the worst value of each component of MODS observed through post-op day 7, hospital discharge, or death, whichever occurred first, even if a subject's worst values for different components occurred on different dates. Subjects who died during this time period were assigned the worst possible follow-up MODS score, 24 points, and each component of MODS was set at 4, which is the worst score. If a subject did not die during this time period but had at least one day where the Glasgow Coma Score couldn't be scored \[subject sedated; neurologic function not normal by pre-op history (prior stroke, tumor or trauma sequelae, cognitively challenged, behavioral disorder, etc.) or intra-op history, but currently unable to assess because of sedation\], then a post-op MODS score was set to missing and a 7-day ΔMODS was not computed. The total MODS score ranges from 0 (best possible) to 24 points (worst possible).

Outcome measures

Outcome measures
Measure
Shorter-storage Red Blood Cell Units
n=534 Participants
Red blood cell units stored \<= 10 days Red blood cell units stored \<= 10 days: Pre-storage leukoreduced red blood cell units stored \<=10 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
Longer-storage Red Blood Cell Units
n=553 Participants
Red blood cell units stored \>= 21 days Red blood cell units stored \>= 21 days: Pre-storage leukoreduced red blood cell units stored \>=21 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
The Change in the Composite Multiple Organ Dysfunction Score (MODS) From the Pre-operative Baseline. The Worst Post-operative Values of Each Component of MODS Will be Used to Calculate the Change in MODS.
8.49 MOD score points
Standard Deviation 3.62
8.66 MOD score points
Standard Deviation 3.55

SECONDARY outcome

Timeframe: 28 days post-surgery

Population: Analysis is restricted to evaluable subjects (defined as randomized subjects who underwent cardiac surgery within 30 days after randomization and received at least one RBC transfusion between randomization and post-operative hour 96).

Subjects were randomized for RECESS no earlier than one calendar day before the planned date of surgery, and were followed for all-cause mortality until post-operative Day 28, death, or study withdrawal, whichever occurred first. In some cases the surgery was postponed after randomization had already occurred. If surgery did not occur within 30 days after randomization, the subject ended the study and was not considered evaluable. If surgery did occur within 30 days after randomization, and the subject received at least one RBC transfusion between randomization and 96 hours after the end of surgery, the subject was considered evaluable. Therefore, in a few evaluable subjects, post-operative Day 28 could be nearly two months after the date of randomization. The times in the time-to-event analysis started at randomization.

Outcome measures

Outcome measures
Measure
Shorter-storage Red Blood Cell Units
n=538 Participants
Red blood cell units stored \<= 10 days Red blood cell units stored \<= 10 days: Pre-storage leukoreduced red blood cell units stored \<=10 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
Longer-storage Red Blood Cell Units
n=560 Participants
Red blood cell units stored \>= 21 days Red blood cell units stored \>= 21 days: Pre-storage leukoreduced red blood cell units stored \>=21 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
All-cause Mortality
23 participants with event
29 participants with event

SECONDARY outcome

Timeframe: Through 28 days post-surgery, hospital discharge, or death, whichever occurs first

Population: Analysis is restricted to evaluable subjects (defined as randomized subjects who underwent cardiac surgery within 30 days after randomization and received at least one RBC transfusion between randomization and post-operative hour 96).

The follow-up MODS used to calculate 28-day ΔMODS from pre-op baseline was based on the worst value of each component of MODS observed through post-op day 28, hospital discharge, or death, whichever occurred first, even if a subject's worst values for different components occurred on different dates. Subjects who died during this time period were assigned the worst possible follow-up MODS score, 24 points, and each component of MODS was set at 4, which is the worst score. If a subject did not die during this time period but had at least one day where the Glasgow Coma Score couldn't be scored\[subject sedated; neurologic function not normal by pre-op history (prior stroke, tumor or trauma sequelae, cognitively challenged, behavioral disorder, etc.) or intra-op history, but currently unable to assess because of sedation\], then a post-op MODS score was set to missing and a 28-day ΔMODS was not computed. The total MODS score ranges from 0 (best possible) to 24 points (worst possible).

Outcome measures

Outcome measures
Measure
Shorter-storage Red Blood Cell Units
n=531 Participants
Red blood cell units stored \<= 10 days Red blood cell units stored \<= 10 days: Pre-storage leukoreduced red blood cell units stored \<=10 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
Longer-storage Red Blood Cell Units
n=555 Participants
Red blood cell units stored \>= 21 days Red blood cell units stored \>= 21 days: Pre-storage leukoreduced red blood cell units stored \>=21 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
Change in Multiple Organ Dysfunction Score From Pre-operative Baseline.
8.74 MOD score points
Standard Deviation 4.04
9.07 MOD score points
Standard Deviation 4.22

SECONDARY outcome

Timeframe: Through post-operative day 7, hospital discharge, or death, whichever occurs first

Population: Analysis is restricted to evaluable subjects (defined as randomized subjects who underwent cardiac surgery within 30 days after randomization and received at least one RBC transfusion between randomization and post-operative hour 96).

Outcome measures

Outcome measures
Measure
Shorter-storage Red Blood Cell Units
n=448 Participants
Red blood cell units stored \<= 10 days Red blood cell units stored \<= 10 days: Pre-storage leukoreduced red blood cell units stored \<=10 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
Longer-storage Red Blood Cell Units
n=470 Participants
Red blood cell units stored \>= 21 days Red blood cell units stored \>= 21 days: Pre-storage leukoreduced red blood cell units stored \>=21 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
Composite of Major In-hospital Post-operative Complications (Death, Stroke, Myocardial Infarction, Renal Failure, Culture-proven Sepsis/Septic Shock)
91 participants with event
87 participants with event

SECONDARY outcome

Timeframe: Through post-operative day 7, hospital discharge, or death, whichever occurs first

Population: Analysis is restricted to evaluable subjects (defined as randomized subjects who underwent cardiac surgery within 30 days after randomization and received at least one RBC transfusion between randomization and post-operative hour 96).

Outcome measures

Outcome measures
Measure
Shorter-storage Red Blood Cell Units
n=472 Participants
Red blood cell units stored \<= 10 days Red blood cell units stored \<= 10 days: Pre-storage leukoreduced red blood cell units stored \<=10 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
Longer-storage Red Blood Cell Units
n=496 Participants
Red blood cell units stored \>= 21 days Red blood cell units stored \>= 21 days: Pre-storage leukoreduced red blood cell units stored \>=21 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
Composite of Major Cardiac Events (Death, Myocardial Infarction, Low Cardiac Output, Ventricular Tachycardia, Ventricular Fibrillation)
206 participants with event
230 participants with event

SECONDARY outcome

Timeframe: Through post-operative day 7, hospital discharge, or death, whichever occurs first

Population: Analysis is restricted to evaluable subjects (defined as randomized subjects who underwent cardiac surgery within 30 days after randomization and received at least one RBC transfusion between randomization and post-operative hour 96).

Outcome measures

Outcome measures
Measure
Shorter-storage Red Blood Cell Units
n=508 Participants
Red blood cell units stored \<= 10 days Red blood cell units stored \<= 10 days: Pre-storage leukoreduced red blood cell units stored \<=10 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
Longer-storage Red Blood Cell Units
n=537 Participants
Red blood cell units stored \>= 21 days Red blood cell units stored \>= 21 days: Pre-storage leukoreduced red blood cell units stored \>=21 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
Composite of Major Pulmonary Events (Any Mechanical Ventilation From 48 Hours Post-operation to Day 7, Hospital Discharge or Death, Whichever Comes First, or Pulmonary Embolism)
62 participants with event
75 participants with event

SECONDARY outcome

Timeframe: Through post-operative day 28, hospital discharge, or death, whichever occurs first

Population: Analysis is restricted to evaluable subjects (defined as randomized subjects who underwent cardiac surgery within 30 days after randomization and received at least one RBC transfusion between randomization and post-operative hour 96).

Because some subjects may experience multiple periods of ventilator use, the total duration that they were on a ventilator was compared between the two groups.

Outcome measures

Outcome measures
Measure
Shorter-storage Red Blood Cell Units
n=514 Participants
Red blood cell units stored \<= 10 days Red blood cell units stored \<= 10 days: Pre-storage leukoreduced red blood cell units stored \<=10 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
Longer-storage Red Blood Cell Units
n=540 Participants
Red blood cell units stored \>= 21 days Red blood cell units stored \>= 21 days: Pre-storage leukoreduced red blood cell units stored \>=21 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
Ventilation Duration
2.7 days
Standard Deviation 3.9
2.8 days
Standard Deviation 4.3

SECONDARY outcome

Timeframe: Through post-operative day 7, hospital discharge, or death, whichever occurs first

Population: Analysis is restricted to evaluable subjects (defined as randomized subjects who underwent cardiac surgery within 30 days after randomization and received at least one RBC transfusion between randomization and post-operative hour 96).

Outcome measures

Outcome measures
Measure
Shorter-storage Red Blood Cell Units
n=532 Participants
Red blood cell units stored \<= 10 days Red blood cell units stored \<= 10 days: Pre-storage leukoreduced red blood cell units stored \<=10 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
Longer-storage Red Blood Cell Units
n=558 Participants
Red blood cell units stored \>= 21 days Red blood cell units stored \>= 21 days: Pre-storage leukoreduced red blood cell units stored \>=21 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
Change in Serum Creatinine From Pre-operative Value to Worst Post-operative Value
0.35 mg/dL
Standard Deviation 0.58
0.35 mg/dL
Standard Deviation 0.51

SECONDARY outcome

Timeframe: Through post-operative day 7, hospital discharge, or death, whichever occurs first

Population: Analysis is restricted to evaluable subjects (defined as randomized subjects who underwent cardiac surgery within 30 days after randomization and received at least one RBC transfusion between randomization and post-operative hour 96).

Outcome measures

Outcome measures
Measure
Shorter-storage Red Blood Cell Units
n=443 Participants
Red blood cell units stored \<= 10 days Red blood cell units stored \<= 10 days: Pre-storage leukoreduced red blood cell units stored \<=10 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
Longer-storage Red Blood Cell Units
n=470 Participants
Red blood cell units stored \>= 21 days Red blood cell units stored \>= 21 days: Pre-storage leukoreduced red blood cell units stored \>=21 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
Change in Troponin-I From Pre-operative Value to Worst Post-operative Value
15.82 ng/mL
Standard Deviation 37.64
14.06 ng/mL
Standard Deviation 23.77

SECONDARY outcome

Timeframe: Through post-operative day 7, hospital discharge, or death, whichever occurs first

Population: Analysis is restricted to evaluable subjects (defined as randomized subjects who underwent cardiac surgery within 30 days after randomization and received at least one RBC transfusion between randomization and post-operative hour 96).

The arterial lactate levels were adjusted to make them comparable to venous lactate levels.

Outcome measures

Outcome measures
Measure
Shorter-storage Red Blood Cell Units
n=410 Participants
Red blood cell units stored \<= 10 days Red blood cell units stored \<= 10 days: Pre-storage leukoreduced red blood cell units stored \<=10 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
Longer-storage Red Blood Cell Units
n=437 Participants
Red blood cell units stored \>= 21 days Red blood cell units stored \>= 21 days: Pre-storage leukoreduced red blood cell units stored \>=21 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
Change in Lactate From Pre-operative Value to Worst Post-operative Value
2.30 mmol/L
Standard Deviation 3.33
2.92 mmol/L
Standard Deviation 5.97

SECONDARY outcome

Timeframe: Through post-operative day 7, hospital discharge, or death, whichever occurs first

Population: Analysis is restricted to evaluable subjects (defined as randomized subjects who underwent cardiac surgery within 30 days after randomization and received at least one RBC transfusion between randomization and post-operative hour 96).

Outcome measures

Outcome measures
Measure
Shorter-storage Red Blood Cell Units
n=513 Participants
Red blood cell units stored \<= 10 days Red blood cell units stored \<= 10 days: Pre-storage leukoreduced red blood cell units stored \<=10 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
Longer-storage Red Blood Cell Units
n=543 Participants
Red blood cell units stored \>= 21 days Red blood cell units stored \>= 21 days: Pre-storage leukoreduced red blood cell units stored \>=21 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
Change in Bilirubin From Pre-operative Value to Worst Post-operative Value
0.85 mg/dL
Standard Deviation 1.24
1.49 mg/dL
Standard Deviation 2.53

SECONDARY outcome

Timeframe: Through post-operative day 7, hospital discharge, or death, whichever occurs first

Population: Only 4 pediatric subjects were enrolled. One treatment arm had only one subject with available data for analyzing the change in ALT. Therefore, to protect patient confidentiality, results were not entered.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Through post-operative day 28, hospital discharge, or death, whichever occurs first

Population: Analysis is restricted to evaluable subjects (defined as randomized subjects who underwent cardiac surgery within 30 days after randomization and received at least one RBC transfusion between randomization and post-operative hour 96). The mean time to an event is estimated by the area under the survival function.

Subjects were randomized for RECESS no earlier than one calendar day before the planned date of surgery, and were followed until post-operative Day 28, death, or study withdrawal, whichever occurred first. In some cases the surgery was postponed after randomization had already occurred. If surgery did not occur within 30 days after randomization, the subject ended the study and was not considered evaluable. If surgery did occur within 30 days after randomization, and the subject received at least one RBC transfusion between randomization and 96 hours after the end of surgery, the subject was considered evaluable. Therefore, in a few evaluable subjects, post-operative Day 28 could be nearly two months after the date of randomization. The times in the time-to-event analyses are from randomization to first post-operative bowel movement.

Outcome measures

Outcome measures
Measure
Shorter-storage Red Blood Cell Units
n=538 Participants
Red blood cell units stored \<= 10 days Red blood cell units stored \<= 10 days: Pre-storage leukoreduced red blood cell units stored \<=10 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
Longer-storage Red Blood Cell Units
n=560 Participants
Red blood cell units stored \>= 21 days Red blood cell units stored \>= 21 days: Pre-storage leukoreduced red blood cell units stored \>=21 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
Days to First Bowel Movement
5.89 days
Standard Error 0.17
6.62 days
Standard Error 0.25

SECONDARY outcome

Timeframe: Through post-operative day 28, hospital discharge, or death, whichever occurs first

Population: Analysis is restricted to evaluable subjects (defined as randomized subjects who underwent cardiac surgery within 30 days after randomization and received at least one RBC transfusion between randomization and post-operative hour 96). The mean time to an event is estimated by the area under the survival function.

Subjects were randomized for RECESS no earlier than one calendar day before the planned date of surgery, and were followed until post-operative Day 28, death, or study withdrawal, whichever occurred first. In some cases the surgery was postponed after randomization had already occurred. If surgery did not occur within 30 days after randomization, the subject ended the study and was not considered evaluable. If surgery did occur within 30 days after randomization, and the subject received at least one RBC transfusion between randomization and 96 hours after the end of surgery, the subject was considered evaluable. Therefore, in a few evaluable subjects, post-operative Day 28 could be nearly two months after the date of randomization. The times in the time-to-event analyses are from randomization to first post-operative solid food.

Outcome measures

Outcome measures
Measure
Shorter-storage Red Blood Cell Units
n=538 Participants
Red blood cell units stored \<= 10 days Red blood cell units stored \<= 10 days: Pre-storage leukoreduced red blood cell units stored \<=10 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
Longer-storage Red Blood Cell Units
n=560 Participants
Red blood cell units stored \>= 21 days Red blood cell units stored \>= 21 days: Pre-storage leukoreduced red blood cell units stored \>=21 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
Days to First Solid Food
5.73 days
Standard Error 0.37
6.18 days
Standard Error 0.35

SECONDARY outcome

Timeframe: Through post-op day 28

Population: Analysis is restricted to evaluable subjects (defined as randomized subjects who underwent cardiac surgery within 30 days after randomization and received at least one RBC transfusion between randomization and post-operative hour 96).

Outcome measures

Outcome measures
Measure
Shorter-storage Red Blood Cell Units
n=511 Participants
Red blood cell units stored \<= 10 days Red blood cell units stored \<= 10 days: Pre-storage leukoreduced red blood cell units stored \<=10 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
Longer-storage Red Blood Cell Units
n=539 Participants
Red blood cell units stored \>= 21 days Red blood cell units stored \>= 21 days: Pre-storage leukoreduced red blood cell units stored \>=21 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
Days Alive and Ventilator Free Through Post-op Day 28
25.38 days
Standard Deviation 6.40
25.17 days
Standard Deviation 6.75

SECONDARY outcome

Timeframe: 48 hours post-operation through day 28, hospital discharge, or death, whichever occurs first

Population: Analysis is restricted to evaluable subjects (defined as randomized subjects who underwent cardiac surgery within 30 days after randomization and received at least one RBC transfusion between randomization and post-operative hour 96).

Outcome measures

Outcome measures
Measure
Shorter-storage Red Blood Cell Units
n=508 Participants
Red blood cell units stored \<= 10 days Red blood cell units stored \<= 10 days: Pre-storage leukoreduced red blood cell units stored \<=10 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
Longer-storage Red Blood Cell Units
n=537 Participants
Red blood cell units stored \>= 21 days Red blood cell units stored \>= 21 days: Pre-storage leukoreduced red blood cell units stored \>=21 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
Any Mechanical Ventilation More Than 48 Hours Post-operation
68 participants with event
80 participants with event

Adverse Events

Shorter-storage Red Blood Cell Units

Serious events: 283 serious events
Other events: 324 other events
Deaths: 0 deaths

Longer-storage Red Blood Cell Units

Serious events: 288 serious events
Other events: 334 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Shorter-storage Red Blood Cell Units
n=538 participants at risk
Red blood cell units stored \<= 10 days Red blood cell units stored \<= 10 days: Pre-storage leukoreduced red blood cell units stored \<=10 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
Longer-storage Red Blood Cell Units
n=560 participants at risk
Red blood cell units stored \>= 21 days Red blood cell units stored \>= 21 days: Pre-storage leukoreduced red blood cell units stored \>=21 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
Blood and lymphatic system disorders
Anaemia
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.36%
2/560 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Blood and lymphatic system disorders
Autoimmune thrombocytopenia
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Blood and lymphatic system disorders
Coagulopathy
0.37%
2/538 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.36%
2/560 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Blood and lymphatic system disorders
Disseminated intravascular coagulation
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Blood and lymphatic system disorders
Haemolytic anaemia
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Blood and lymphatic system disorders
Heparin-induced thrombocytopenia
0.93%
5/538 • Number of events 5 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.54%
3/560 • Number of events 3 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Blood and lymphatic system disorders
Leukocytosis
1.3%
7/538 • Number of events 7 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.71%
4/560 • Number of events 5 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Blood and lymphatic system disorders
Thrombocytopenia
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.71%
4/560 • Number of events 4 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Accelerated idioventricular rhythm
0.56%
3/538 • Number of events 4 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Acute coronary syndrome
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Acute myocardial infarction
1.7%
9/538 • Number of events 9 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
1.6%
9/560 • Number of events 9 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Acute right ventricular failure
0.37%
2/538 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Angina pectoris
0.37%
2/538 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Angina unstable
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Arrhythmia
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.36%
2/560 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Arrhythmia supraventricular
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Atrial fibrillation
5.8%
31/538 • Number of events 33 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
4.5%
25/560 • Number of events 28 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Atrial flutter
0.56%
3/538 • Number of events 3 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Atrial tachycardia
0.56%
3/538 • Number of events 3 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.54%
3/560 • Number of events 3 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Atrioventricular block
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Atrioventricular block complete
0.56%
3/538 • Number of events 3 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.54%
3/560 • Number of events 3 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Atrioventricular block first degree
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Bradycardia
1.3%
7/538 • Number of events 9 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
1.8%
10/560 • Number of events 10 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Cardiac arrest
0.56%
3/538 • Number of events 4 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.71%
4/560 • Number of events 4 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Cardiac disorder
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Cardiac failure congestive
0.37%
2/538 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.54%
3/560 • Number of events 3 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Cardiac tamponade
1.1%
6/538 • Number of events 6 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.89%
5/560 • Number of events 6 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Cardio-respiratory arrest
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Cardiogenic shock
1.7%
9/538 • Number of events 9 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
2.3%
13/560 • Number of events 13 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Cardiomyopathy acute
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Conduction disorder
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Intracardiac thrombus
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Myocardial infarction
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Negative cardiac inotropic effect
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Nodal arrhythmia
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Pericardial effusion
0.56%
3/538 • Number of events 3 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Sick sinus syndrome
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.36%
2/560 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Sinus bradycardia
3.7%
20/538 • Number of events 20 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
4.3%
24/560 • Number of events 24 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Sinus tachycardia
3.0%
16/538 • Number of events 17 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
4.6%
26/560 • Number of events 28 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Supraventricular tachyarrhythmia
0.56%
3/538 • Number of events 3 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.36%
2/560 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Supraventricular tachycardia
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.54%
3/560 • Number of events 3 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Tachycardia
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.89%
5/560 • Number of events 6 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Ventricular arrhythmia
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Ventricular asystole
0.37%
2/538 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.36%
2/560 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Ventricular extrasystoles
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.36%
2/560 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Ventricular fibrillation
0.74%
4/538 • Number of events 4 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
1.1%
6/560 • Number of events 6 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Ventricular tachyarrhythmia
0.56%
3/538 • Number of events 4 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.71%
4/560 • Number of events 4 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Ventricular tachycardia
1.1%
6/538 • Number of events 9 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
1.2%
7/560 • Number of events 8 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Congenital, familial and genetic disorders
Familial hypocalciuric hypercalcaemia
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Congenital, familial and genetic disorders
Heart block congenital
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.36%
2/560 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Ear and labyrinth disorders
Vertigo
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Endocrine disorders
Antidiuretic hormone abnormality
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Eye disorders
Visual acuity reduced transiently
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Eye disorders
Visual impairment
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Gastrointestinal disorders
Abdominal compartment syndrome
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Gastrointestinal disorders
Abdominal distension
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Gastrointestinal disorders
Ascites
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Gastrointestinal disorders
Colitis
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Gastrointestinal disorders
Colonic obstruction
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Gastrointestinal disorders
Dysphagia
0.56%
3/538 • Number of events 3 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Gastrointestinal disorders
Gastric haemorrhage
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.36%
2/560 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Gastrointestinal disorders
Gastric perforation
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Gastrointestinal disorders
Gastrointestinal haemorrhage
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.36%
2/560 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Gastrointestinal disorders
Ileus
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Gastrointestinal disorders
Ileus paralytic
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Gastrointestinal disorders
Internal hernia
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Gastrointestinal disorders
Lower gastrointestinal haemorrhage
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Gastrointestinal disorders
Megacolon
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Gastrointestinal disorders
Mesenteric occlusion
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Gastrointestinal disorders
Oesophageal perforation
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Gastrointestinal disorders
Peritoneal haemorrhage
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Gastrointestinal disorders
Pneumoperitoneum
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Gastrointestinal disorders
Retroperitoneal haematoma
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Gastrointestinal disorders
Retroperitoneal haemorrhage
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Gastrointestinal disorders
Upper gastrointestinal haemorrhage
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
General disorders
Adverse drug reaction
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
General disorders
Application site bleeding
2.4%
13/538 • Number of events 13 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
2.0%
11/560 • Number of events 11 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
General disorders
Cardiac death
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
General disorders
Chest discomfort
0.37%
2/538 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
General disorders
Chest pain
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
General disorders
Infusion related reaction
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
General disorders
Infusion site dermatitis
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
General disorders
Multi-organ disorder
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
General disorders
Multi-organ failure
0.56%
3/538 • Number of events 3 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.54%
3/560 • Number of events 3 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
General disorders
Pyrexia
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Hepatobiliary disorders
Hepatic cirrhosis
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Hepatobiliary disorders
Hepatic ischaemia
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Hepatobiliary disorders
Hyperbilirubinaemia
4.8%
26/538 • Number of events 28 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
9.1%
51/560 • Number of events 58 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Hepatobiliary disorders
Liver injury
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Hepatobiliary disorders
Pneumobilia
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Immune system disorders
Anaphylactoid shock
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Abdominal infection
0.19%
1/538 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.36%
2/560 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Abdominal sepsis
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.36%
2/560 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Acute endocarditis
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Adenoviral upper respiratory infection
0.37%
2/538 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Bacterial diarrhoea
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Bacterial infection
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Bacterial sepsis
0.56%
3/538 • Number of events 3 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
1.1%
6/560 • Number of events 6 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Bronchitis
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Bronchitis pneumococcal
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Bronchopneumonia
2.0%
11/538 • Number of events 12 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
1.6%
9/560 • Number of events 9 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Candida pneumonia
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Cellulitis
0.56%
3/538 • Number of events 3 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Clostridium colitis
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Respiratory, thoracic and mediastinal disorders
Acute respiratory failure
1.7%
9/538 • Number of events 10 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
2.0%
11/560 • Number of events 11 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Clostridium difficile colitis
0.56%
3/538 • Number of events 3 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.54%
3/560 • Number of events 3 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Cystitis
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Cystitis klebsiella
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Endocarditis
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Enterobacter infection
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Enterobacter pneumonia
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.36%
2/560 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Enterococcal infection
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Escherichia urinary tract infection
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Febrile infection
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.54%
3/560 • Number of events 3 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Genitourinary tract infection
1.5%
8/538 • Number of events 9 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
1.1%
6/560 • Number of events 6 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Incision site infection
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Infection
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Lung infection
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Osteomyelitis
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Pneumonia klebsiella
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Post procedural infection
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Postoperative wound infection
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.36%
2/560 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Pseudomonal bacteraemia
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Pseudomonas infection
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Sepsis syndrome
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Septic shock
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Serratia infection
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Upper respiratory tract infection
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Urinary tract infection
0.37%
2/538 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Injury, poisoning and procedural complications
Airway complication of anaesthesia
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Injury, poisoning and procedural complications
Allergic transfusion reaction
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Injury, poisoning and procedural complications
Anaphylactic transfusion reaction
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Injury, poisoning and procedural complications
Cardiac function disturbance postoperative
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Injury, poisoning and procedural complications
Cardiac valve replacement complication
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Injury, poisoning and procedural complications
Confusion postoperative
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Injury, poisoning and procedural complications
Deep vein thrombosis postoperative
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.71%
4/560 • Number of events 4 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Injury, poisoning and procedural complications
Endotracheal intubation complication
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Injury, poisoning and procedural complications
Fall
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Injury, poisoning and procedural complications
Iatrogenic injury
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Injury, poisoning and procedural complications
Mental status changes postoperative
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.36%
2/560 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Injury, poisoning and procedural complications
Operative haemorrhage
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Injury, poisoning and procedural complications
Pneumothorax traumatic
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Injury, poisoning and procedural complications
Post procedural complication
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Injury, poisoning and procedural complications
Post procedural haemorrhage
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
1.1%
6/560 • Number of events 6 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Injury, poisoning and procedural complications
Post procedural myocardial infarction
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Respiratory, thoracic and mediastinal disorders
Anaemic hypoxia
0.56%
3/538 • Number of events 3 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
1.1%
6/560 • Number of events 6 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Injury, poisoning and procedural complications
Postoperative ileus
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Injury, poisoning and procedural complications
Postoperative renal failure
0.56%
3/538 • Number of events 3 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.54%
3/560 • Number of events 3 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Injury, poisoning and procedural complications
Procedural hypotension
0.56%
3/538 • Number of events 3 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
1.6%
9/560 • Number of events 9 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Injury, poisoning and procedural complications
Renal injury
0.37%
2/538 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.36%
2/560 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Injury, poisoning and procedural complications
Subdural haematoma
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Injury, poisoning and procedural complications
Urinary retention postoperative
1.9%
10/538 • Number of events 10 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
1.8%
10/560 • Number of events 10 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Injury, poisoning and procedural complications
Weaning failure
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Injury, poisoning and procedural complications
Wound dehiscence
0.37%
2/538 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Injury, poisoning and procedural complications
Wound necrosis
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
Activated partial thromboplastin time
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
Anticoagulation drug level below therapeutic
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
Aspiration pleural cavity
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
Bacteria blood identified
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
Bacteria sputum identified
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
Blood gases abnormal
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
Blood pressure abnormal
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
Blood pressure decreased
1.1%
6/538 • Number of events 6 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.89%
5/560 • Number of events 5 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
Blood pressure systolic decreased
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
Blood urea nitrogen/creatinine ratio increased
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
Blood urine present
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
Body temperature decreased
0.37%
2/538 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
Body temperature increased
0.37%
2/538 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.54%
3/560 • Number of events 3 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
Bronchoalveolar lavage abnormal
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
Cardiac enzymes increased
0.37%
2/538 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.36%
2/560 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
Cardiac output decreased
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
Clostridium difficile toxin test positive
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
ECG signs of myocardial ischaemia
0.74%
4/538 • Number of events 4 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.36%
2/560 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
Ejection fraction decreased
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
Fungus culture positive
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
Heart rate decreased
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.36%
2/560 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
Heart rate increased
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
International normalised ratio abnormal
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
Kidney injury molecule-1
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
Methicillin-resistant staphylococcal aureus test positive
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
NIH stroke scale
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
NIH stroke scale score increased
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
Occult blood positive
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
Oxygen saturation
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
Oxygen saturation decreased
0.37%
2/538 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
Pathology test
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
Radial pulse abnormal
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
Red blood cells urine positive
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
Sputum culture positive
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
Transaminases increased
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
Troponin I increased
0.37%
2/538 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
Urine output decreased
2.8%
15/538 • Number of events 15 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
3.2%
18/560 • Number of events 18 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
White blood cell count increased
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Metabolism and nutrition disorders
Acidosis
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Metabolism and nutrition disorders
Feeding disorder
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Metabolism and nutrition disorders
Fluid overload
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.36%
2/560 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Metabolism and nutrition disorders
Fluid retention
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Metabolism and nutrition disorders
Hypercalcaemia
0.37%
2/538 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
1.2%
7/560 • Number of events 8 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Metabolism and nutrition disorders
Hyperkalaemia
2.8%
15/538 • Number of events 15 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
2.7%
15/560 • Number of events 16 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Metabolism and nutrition disorders
Hypernatraemia
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Metabolism and nutrition disorders
Hyperphosphataemia
0.93%
5/538 • Number of events 5 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
1.1%
6/560 • Number of events 6 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Metabolism and nutrition disorders
Hyperphosphatasaemia
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Metabolism and nutrition disorders
Hypervolaemia
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Metabolism and nutrition disorders
Hypocalcaemia
10.2%
55/538 • Number of events 56 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
8.2%
46/560 • Number of events 52 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Metabolism and nutrition disorders
Hypoglycaemia
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Metabolism and nutrition disorders
Hypokalaemia
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Metabolism and nutrition disorders
Hyponatraemia
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Metabolism and nutrition disorders
Hypophosphataemia
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Metabolism and nutrition disorders
Hypovolaemia
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Metabolism and nutrition disorders
Malnutrition
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Metabolism and nutrition disorders
Metabolic acidosis
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Metabolism and nutrition disorders
Metabolic alkalosis
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Musculoskeletal and connective tissue disorders
Compartment syndrome
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Musculoskeletal and connective tissue disorders
Hypercreatinaemia
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Nervous system disorders
Altered state of consciousness
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Nervous system disorders
Anoxic encephalopathy
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.36%
2/560 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Nervous system disorders
Aphasia
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Nervous system disorders
Atonic seizures
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Nervous system disorders
Brain stem stroke
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Nervous system disorders
Cerebellar infarction
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Nervous system disorders
Cerebral artery embolism
0.37%
2/538 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Nervous system disorders
Cerebral infarction
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Nervous system disorders
Cerebral venous thrombosis
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Nervous system disorders
Cerebrovascular accident
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Nervous system disorders
Depressed level of consciousness
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Nervous system disorders
Embolic stroke
0.93%
5/538 • Number of events 5 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.54%
3/560 • Number of events 3 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Nervous system disorders
Encephalopathy
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Nervous system disorders
Essential tremor
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Nervous system disorders
Grand mal convulsion
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Nervous system disorders
Hemiparesis
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.36%
2/560 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Nervous system disorders
Ischaemic stroke
0.93%
5/538 • Number of events 5 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.36%
2/560 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Nervous system disorders
Partial seizures
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Nervous system disorders
Seizure anoxic
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Nervous system disorders
Serotonin syndrome
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Nervous system disorders
Simple partial seizures
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Nervous system disorders
Stroke in evolution
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Nervous system disorders
Subarachnoid haemorrhage
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Nervous system disorders
Transient ischaemic attack
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Psychiatric disorders
Adjustment disorder with depressed mood
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Psychiatric disorders
Confusional state
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Psychiatric disorders
Paranoia
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Renal and urinary disorders
Acute prerenal failure
2.8%
15/538 • Number of events 16 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
2.5%
14/560 • Number of events 14 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Renal and urinary disorders
Anuria
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Renal and urinary disorders
Azotaemia
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Renal and urinary disorders
Haematuria
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Renal and urinary disorders
Haemoglobinuria
0.37%
2/538 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.36%
2/560 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Renal and urinary disorders
Oliguria
0.93%
5/538 • Number of events 5 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.54%
3/560 • Number of events 3 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Renal and urinary disorders
Renal disorder
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Renal and urinary disorders
Renal failure
0.37%
2/538 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.89%
5/560 • Number of events 5 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Renal and urinary disorders
Renal failure acute
1.5%
8/538 • Number of events 8 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.36%
2/560 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Renal and urinary disorders
Renal impairment
0.37%
2/538 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.54%
3/560 • Number of events 3 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Renal and urinary disorders
Renal mass
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Renal and urinary disorders
Renal tubular necrosis
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Renal and urinary disorders
Urinary bladder haemorrhage
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Renal and urinary disorders
Urinary retention
0.56%
3/538 • Number of events 3 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.89%
5/560 • Number of events 5 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Reproductive system and breast disorders
Bleeding anovulatory
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Reproductive system and breast disorders
Scrotal swelling
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Respiratory, thoracic and mediastinal disorders
Acute interstitial pneumonitis
0.56%
3/538 • Number of events 3 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Respiratory, thoracic and mediastinal disorders
Acute lung injury
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Respiratory, thoracic and mediastinal disorders
Acute pulmonary oedema
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Respiratory, thoracic and mediastinal disorders
Acute respiratory distress syndrome
0.74%
4/538 • Number of events 4 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.89%
5/560 • Number of events 5 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Respiratory, thoracic and mediastinal disorders
Apnoeic attack
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Respiratory, thoracic and mediastinal disorders
Aspiration
0.37%
2/538 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Respiratory, thoracic and mediastinal disorders
Atelectasis
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Respiratory, thoracic and mediastinal disorders
Clotted haemothorax
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Respiratory, thoracic and mediastinal disorders
Cough
0.56%
3/538 • Number of events 3 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.89%
5/560 • Number of events 5 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Respiratory, thoracic and mediastinal disorders
Dyspnoea
5.0%
27/538 • Number of events 28 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
4.3%
24/560 • Number of events 25 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Respiratory, thoracic and mediastinal disorders
Dyspnoea at rest
1.5%
8/538 • Number of events 9 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
2.1%
12/560 • Number of events 12 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Respiratory, thoracic and mediastinal disorders
Dyspnoea exertional
1.1%
6/538 • Number of events 6 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
1.1%
6/560 • Number of events 6 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Respiratory, thoracic and mediastinal disorders
Epistaxis
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Respiratory, thoracic and mediastinal disorders
Haemothorax
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Respiratory, thoracic and mediastinal disorders
Hypercapnia
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Respiratory, thoracic and mediastinal disorders
Hypoxia
6.1%
33/538 • Number of events 36 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
7.0%
39/560 • Number of events 39 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Respiratory, thoracic and mediastinal disorders
Idiopathic pneumonia syndrome
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Respiratory, thoracic and mediastinal disorders
Lung consolidation
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Respiratory, thoracic and mediastinal disorders
Mediastinal disorder
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Respiratory, thoracic and mediastinal disorders
Mediastinal haematoma
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Respiratory, thoracic and mediastinal disorders
Mediastinal haemorrhage
1.1%
6/538 • Number of events 6 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
1.1%
6/560 • Number of events 6 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Respiratory, thoracic and mediastinal disorders
Pleural effusion
2.0%
11/538 • Number of events 13 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
1.6%
9/560 • Number of events 9 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Respiratory, thoracic and mediastinal disorders
Pneumothorax
0.56%
3/538 • Number of events 3 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Respiratory, thoracic and mediastinal disorders
Pneumothorax spontaneous tension
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Respiratory, thoracic and mediastinal disorders
Respiratory acidosis
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Respiratory, thoracic and mediastinal disorders
Respiratory distress
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Respiratory, thoracic and mediastinal disorders
Respiratory failure
0.37%
2/538 • Number of events 3 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Respiratory, thoracic and mediastinal disorders
Stridor
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Respiratory, thoracic and mediastinal disorders
Tachypnoea
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.36%
2/560 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Respiratory, thoracic and mediastinal disorders
Thoracic haemorrhage
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Respiratory, thoracic and mediastinal disorders
Vocal cord disorder
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Respiratory, thoracic and mediastinal disorders
Wheezing
1.1%
6/538 • Number of events 7 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
2.1%
12/560 • Number of events 12 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Skin and subcutaneous tissue disorders
Angioedema
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Skin and subcutaneous tissue disorders
Itching scar
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Skin and subcutaneous tissue disorders
Pruritus allergic
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Skin and subcutaneous tissue disorders
Skin ulcer
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Surgical and medical procedures
Abdominal exploration
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Surgical and medical procedures
Allergy prophylaxis
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Surgical and medical procedures
Aneurysm repair
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Surgical and medical procedures
Cardiac pacemaker insertion
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Surgical and medical procedures
Dialysis
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Surgical and medical procedures
Extracorporeal membrane oxygenation
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Surgical and medical procedures
Hypotensive anaesthesia procedure
0.56%
3/538 • Number of events 3 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.36%
2/560 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Surgical and medical procedures
Incisional drainage
0.37%
2/538 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.36%
2/560 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Surgical and medical procedures
Intracerebral haematoma evacuation
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Surgical and medical procedures
Pericardial drainage
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Surgical and medical procedures
Removal of foreign body
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Surgical and medical procedures
Tracheostomy
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Vascular disorders
Accelerated hypertension
0.37%
2/538 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Vascular disorders
Aortic intramural haematoma
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Vascular disorders
Arterial thrombosis
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Vascular disorders
Arteriovenous fistula
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Vascular disorders
Deep vein thrombosis
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Vascular disorders
Diastolic hypertension
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.36%
2/560 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Vascular disorders
Diastolic hypotension
2.6%
14/538 • Number of events 14 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
2.5%
14/560 • Number of events 14 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Vascular disorders
Essential hypertension
0.93%
5/538 • Number of events 5 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.54%
3/560 • Number of events 3 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Vascular disorders
Haematoma
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Vascular disorders
Haemodynamic instability
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Vascular disorders
Haemorrhage
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Vascular disorders
Hypertension
2.4%
13/538 • Number of events 14 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
2.3%
13/560 • Number of events 13 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Vascular disorders
Hypotension
18.0%
97/538 • Number of events 106 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
15.5%
87/560 • Number of events 96 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Vascular disorders
Hypovolaemic shock
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.36%
2/560 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Vascular disorders
Ischaemic limb pain
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Vascular disorders
Labile hypertension
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Vascular disorders
Orthostatic hypotension
0.37%
2/538 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Vascular disorders
Peripheral vascular disorder
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Vascular disorders
Poor peripheral circulation
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Vascular disorders
Venous thrombosis limb
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.

Other adverse events

Other adverse events
Measure
Shorter-storage Red Blood Cell Units
n=538 participants at risk
Red blood cell units stored \<= 10 days Red blood cell units stored \<= 10 days: Pre-storage leukoreduced red blood cell units stored \<=10 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
Longer-storage Red Blood Cell Units
n=560 participants at risk
Red blood cell units stored \>= 21 days Red blood cell units stored \>= 21 days: Pre-storage leukoreduced red blood cell units stored \>=21 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
Injury, poisoning and procedural complications
Iatrogenic injury
0.37%
2/538 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.36%
2/560 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Injury, poisoning and procedural complications
Post procedural haematuria
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.36%
2/560 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Blood and lymphatic system disorders
Haemolysis
0.37%
2/538 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Blood and lymphatic system disorders
Leukocytosis
1.3%
7/538 • Number of events 7 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.71%
4/560 • Number of events 4 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Accessory cardiac pathway
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Acute myocardial infarction
0.56%
3/538 • Number of events 3 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.36%
2/560 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Arrhythmia
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Atrial fibrillation
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Atrial tachycardia
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Bradyarrhythmia
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Bradycardia
0.74%
4/538 • Number of events 4 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
1.8%
10/560 • Number of events 10 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Cardiac failure congestive
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Myocardial infarction
0.37%
2/538 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Myocardial ischaemia
0.37%
2/538 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.36%
2/560 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Sinus bradycardia
2.2%
12/538 • Number of events 12 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
2.0%
11/560 • Number of events 12 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Sinus tachycardia
4.6%
25/538 • Number of events 27 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
5.0%
28/560 • Number of events 28 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Supraventricular tachyarrhythmia
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Supraventricular tachycardia
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Tachycardia
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Ventricular tachyarrhythmia
0.56%
3/538 • Number of events 3 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Cardiac disorders
Ventricular tachycardia
1.3%
7/538 • Number of events 7 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.54%
3/560 • Number of events 3 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Congenital, familial and genetic disorders
Familial hypocalciuric hypercalcaemia
0.74%
4/538 • Number of events 4 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.36%
2/560 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
General disorders
Adverse reaction
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
General disorders
Catheter site phlebitis
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
General disorders
Chest pain
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
General disorders
Chills
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
General disorders
Hyperthermia
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
General disorders
Oedema peripheral
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
General disorders
Pyrexia
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Hepatobiliary disorders
Hyperbilirubinaemia
14.5%
78/538 • Number of events 89 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
17.5%
98/560 • Number of events 107 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Hepatobiliary disorders
Hyperbilirubinaemia neonatal
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Immune system disorders
Alloimmunisation
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Immune system disorders
Hypersensitivity
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Acinetobacter infection
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Actinomycotic pulmonary infection
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Acute sinusitis
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Adenoviral upper respiratory infection
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Application site cellulitis
0.37%
2/538 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Arteriovenous graft site infection
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Aspergillosis oral
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Asymptomatic bacteriuria
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Bacteriuria
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Bronchopneumonia
0.37%
2/538 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.36%
2/560 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Catheter site cellulitis
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Clostridium difficile colitis
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Cytomegalovirus urinary tract infection
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Enterobacter tracheobronchitis
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Escherichia urinary tract infection
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.54%
3/560 • Number of events 3 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Genitourinary tract infection
1.9%
10/538 • Number of events 10 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
1.6%
9/560 • Number of events 10 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Incision site infection
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Influenza
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Klebsiella bacteraemia
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Parotitis
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Upper respiratory fungal infection
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Urinary tract infection
0.37%
2/538 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Urinary tract infection bacterial
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.36%
2/560 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Infections and infestations
Wound infection
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Injury, poisoning and procedural complications
Allergic transfusion reaction
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.36%
2/560 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Injury, poisoning and procedural complications
Postoperative renal failure
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Injury, poisoning and procedural complications
Procedural hypotension
0.56%
3/538 • Number of events 3 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.36%
2/560 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Injury, poisoning and procedural complications
Urethral stricture traumatic
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Injury, poisoning and procedural complications
Urinary retention postoperative
1.3%
7/538 • Number of events 7 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
1.8%
10/560 • Number of events 10 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
Bacteria blood identified
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
Bacteria sputum identified
0.37%
2/538 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
Bacteria urine
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
Bilirubin conjugated abnormal
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
Bilirubin conjugated increased
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.36%
2/560 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
Blood pressure abnormal
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
Blood pressure decreased
0.93%
5/538 • Number of events 5 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.54%
3/560 • Number of events 3 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
Blood pressure orthostatic decreased
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
Blood urine
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
Body temperature increased
1.5%
8/538 • Number of events 8 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.54%
3/560 • Number of events 3 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
Cardiac enzymes increased
1.3%
7/538 • Number of events 7 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
1.6%
9/560 • Number of events 9 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
Differential white blood cell count normal
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
ECG signs of myocardial ischaemia
1.3%
7/538 • Number of events 7 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
1.4%
8/560 • Number of events 8 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
Heart rate decreased
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
Methicillin-resistant staphylococcal aureus test positive
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
Oxygen saturation decreased
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
Sputum culture
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
Sputum culture positive
0.37%
2/538 • Number of events 3 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
Troponin
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Investigations
Urine output decreased
0.56%
3/538 • Number of events 3 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Metabolism and nutrition disorders
Fluid overload
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Metabolism and nutrition disorders
Fluid retention
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Metabolism and nutrition disorders
Hypercalcaemia
0.37%
2/538 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.36%
2/560 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Metabolism and nutrition disorders
Hyperkalaemia
3.3%
18/538 • Number of events 18 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
3.2%
18/560 • Number of events 18 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Metabolism and nutrition disorders
Hyperphosphataemia
4.6%
25/538 • Number of events 30 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
2.0%
11/560 • Number of events 13 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Metabolism and nutrition disorders
Hyperphosphatasaemia
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.54%
3/560 • Number of events 3 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Metabolism and nutrition disorders
Hypocalcaemia
34.8%
187/538 • Number of events 230 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
34.1%
191/560 • Number of events 228 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Metabolism and nutrition disorders
Hyponatraemia
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Metabolism and nutrition disorders
Hypophosphataemia
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.36%
2/560 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Nervous system disorders
Aphasia
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Nervous system disorders
Embolic stroke
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Nervous system disorders
Haemorrhagic stroke
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Renal and urinary disorders
Acute prerenal failure
1.5%
8/538 • Number of events 8 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.89%
5/560 • Number of events 7 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Renal and urinary disorders
Haematuria
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Renal and urinary disorders
Haemoglobinuria
0.37%
2/538 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Renal and urinary disorders
Hypocalciuria
0.56%
3/538 • Number of events 4 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Renal and urinary disorders
Oliguria
0.37%
2/538 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.71%
4/560 • Number of events 4 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Renal and urinary disorders
Renal failure
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.36%
2/560 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Renal and urinary disorders
Renal failure acute
0.37%
2/538 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Renal and urinary disorders
Renal impairment
0.37%
2/538 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.36%
2/560 • Number of events 3 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Renal and urinary disorders
Renal tubular necrosis
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Renal and urinary disorders
Urinary incontinence
0.37%
2/538 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.36%
2/560 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Renal and urinary disorders
Urinary retention
0.93%
5/538 • Number of events 5 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.54%
3/560 • Number of events 3 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Renal and urinary disorders
Urine flow decreased
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Reproductive system and breast disorders
Scrotal oedema
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Respiratory, thoracic and mediastinal disorders
Anaemic hypoxia
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.36%
2/560 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Respiratory, thoracic and mediastinal disorders
Bradypnoea
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Respiratory, thoracic and mediastinal disorders
Cough
0.56%
3/538 • Number of events 3 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.36%
2/560 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Respiratory, thoracic and mediastinal disorders
Dyspnoea
1.9%
10/538 • Number of events 11 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
2.0%
11/560 • Number of events 11 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Respiratory, thoracic and mediastinal disorders
Dyspnoea at rest
0.56%
3/538 • Number of events 3 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.71%
4/560 • Number of events 4 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Respiratory, thoracic and mediastinal disorders
Dyspnoea exertional
2.8%
15/538 • Number of events 16 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
3.6%
20/560 • Number of events 20 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Respiratory, thoracic and mediastinal disorders
Hypoxia
1.5%
8/538 • Number of events 8 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
2.5%
14/560 • Number of events 14 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Respiratory, thoracic and mediastinal disorders
Pleural effusion
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Respiratory, thoracic and mediastinal disorders
Productive cough
0.56%
3/538 • Number of events 3 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.54%
3/560 • Number of events 3 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Respiratory, thoracic and mediastinal disorders
Tachypnoea
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Respiratory, thoracic and mediastinal disorders
Wheezing
3.0%
16/538 • Number of events 17 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
2.1%
12/560 • Number of events 12 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Skin and subcutaneous tissue disorders
Erythema
0.37%
2/538 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Surgical and medical procedures
Haemophilus influenzae type b immunisation
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Surgical and medical procedures
Hypotensive anaesthesia procedure
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Vascular disorders
Accelerated hypertension
0.74%
4/538 • Number of events 4 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.89%
5/560 • Number of events 5 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Vascular disorders
Diastolic hypertension
0.37%
2/538 • Number of events 3 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Vascular disorders
Diastolic hypotension
1.1%
6/538 • Number of events 6 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.71%
4/560 • Number of events 4 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Vascular disorders
Essential hypertension
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.36%
2/560 • Number of events 2 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Vascular disorders
Hypertension
3.7%
20/538 • Number of events 20 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
3.8%
21/560 • Number of events 23 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Vascular disorders
Hypertensive crisis
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Vascular disorders
Hypotension
13.2%
71/538 • Number of events 76 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
13.0%
73/560 • Number of events 76 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Vascular disorders
Orthostatic hypotension
0.00%
0/538 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.18%
1/560 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
Vascular disorders
Thrombophlebitis
0.19%
1/538 • Number of events 1 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.
0.00%
0/560 • Reported Adverse Events (AEs) include any untoward medical occurrence which occurred after a subject gave informed consent and no later than post-operative day 28, hospital discharge, or death, whichever came first.
Data were collected on all serious adverse events (SAEs) and on pre-specified types of non-serious adverse events. If a subject experiences more than one occurrence of a specific adverse event, the subject was counted only once for that adverse event.

Additional Information

Susan Assmann, PhD

New England Research Institutes

Phone: 617-972-3048

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place